Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Levocetirizine
Drug ID BADD_D01272
Description Levocetirizine is a selective histamine H1 antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine].[L7694] Levocetirizine has greater affinity for the histamine H1 receptor than cetirizine.[L7694] Levocetirizine was granted FDA approval in 1995.[L7694]
Indications and Usage Levocetirizine is indicated to treat symptoms of perennial allergic rhinitis and uncomplicated skin manifestations of chronic idiopathic urticaria.[L7694] It is also used over the counter for a variety of mild allergy symptoms.[A181748]
Marketing Status approved
ATC Code R06AE09
DrugBank ID DB06282
KEGG ID D07402
MeSH ID C472067
PubChem ID 1549000
TTD Drug ID D0M8PW
NDC Product Code Not Available
UNII 6U5EA9RT2O
Synonyms levocetirizine | levocetrizine | acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)- | (2-(4-((R)-p-chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)acetic acid | levocetirizine hydrochloride | Xusal | levocetirizine dihydrochloride | (2-(4-((R)-(4-chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic acid dihydrochloride | cetirizine (R)-form dihydrochloride | acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, dihydrochloride | Xyzal | UCB-28556
Chemical Information
Molecular Formula C21H25ClN2O3
CAS Registry Number 130018-77-8
SMILES C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urinary retention20.02.02.011--
Urticaria10.01.06.001; 23.04.02.0010.000194%
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.0070.000130%
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.0030.000194%
Weight increased13.15.01.006--
General physical health deterioration08.01.03.0180.000130%Not Available
Urticaria chronic23.04.02.009; 10.01.06.009--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Cerebral disorder17.02.10.0170.000130%Not Available
Paraesthesia oral17.02.06.008; 07.05.05.0350.000130%Not Available
Cognitive disorder17.03.03.003; 19.21.02.0010.000130%
Mental disorder19.07.01.0020.000194%Not Available
Drug intolerance08.06.01.0130.000130%Not Available
Drug-induced liver injury12.03.01.044; 09.01.07.0230.000194%Not Available
Dermatitis exfoliative generalised23.03.07.002; 10.01.01.0290.000130%Not Available
Sopor19.02.04.002; 17.02.04.0210.000259%Not Available
Eosinophilic oesophagitis10.01.01.030; 07.08.05.006; 01.02.04.0160.000194%Not Available
Fixed eruption23.03.05.008; 10.01.01.037; 08.01.06.025--Not Available
Mast cell activation syndrome10.02.01.090; 01.05.01.0300.000130%Not Available
Therapeutic product effect decreased08.06.01.0500.000441%Not Available
The 4th Page    First    Pre   4    Total 4 Pages